Clinical translation of immunoliposomes for cancer therapy: recent perspectives

Wang, Di; Sun, Yating; Liu, Yange; Meng, Fanchao; Lee, Robert J.

doi:10.1080/17425247.2018.1517747

Cited by 53 publications

(36 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our chosen PLGA-and lipid-based nanoparticle delivery constructs have previously shown in vivo compatibility and biodegradability and are approved for human usage by the US Food and Drug Administration (FDA), making them ideal for clinical application. [37][38][39][40][41] In these studies, we specifically demonstrate improved efficiency for encapsulated PLGA or liposome nanoparticles to deliver our immunogenic BCMA peptide to human dendritic cells, as compared to free peptide alone. Both nanoparticle constructs exhibit uniform size distribution, had similar efficiency of BCMA peptide encapsulation and provide improved peptide delivery to dendritic cells.…”

Section: Discussionmentioning

confidence: 89%

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications

Bae

Parayath

et al. 2019

Leukemia

View full text Add to dashboard Cite

Objective: The purpose of these studies was to develop and characterize B-cell Maturation Antigen (BCMA)-specific peptide encapsulated nanoparticle formulations to efficiently evoke BCMA-specific CD8 + cytotoxic T lymphocytes (CTL) with poly-functional immune activities against multiple myeloma (MM). Findings: Heteroclitic BCMA 72-80 [YLMFLLRKI] peptide encapsulated liposome or poly(lactic-co-glycolic acid) (PLGA) nanoparticles displayed uniform size distribution and increased peptide delivery to human dendritic cells which enhanced induction of BCMA-specific CTL. Distinct from liposome-based nanoparticles, PLGA-based nanoparticles demonstrated a gradual increase in peptide uptake by antigen-presenting cells, and induced BCMA-specific CTL with higher anti-tumor activities (CD107a degranulation, CTL proliferation, and IFN-γ/IL-2/TNFα production) against primary CD138 + tumor cells and MM cell lines. The improved functional activities were associated with increased Tetramer + /CD45RO + memory CTL, CD28 upregulation on Tetramer + CTL, and longer maintenance of central memory (CCR7 + CD45RO +) CTL, with the highest anti-MM activity and less differentiation into effector memory (CCR7 − CD45RO +) CTL. Conclusion: These results provide the framework for therapeutic application of PLGA-based BCMA peptide delivery system, rather than free peptide, to enhance the induction of BCMAspecific CTL with poly-functional Th1-specific anti-MM activities.

show abstract

Section: Discussionmentioning

confidence: 89%

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications

Bae

Parayath

et al. 2019

Leukemia

View full text Add to dashboard Cite

show abstract

“…However, the first immunoliposome has yet to become approved by the American Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and only few of clinical trials are reported. Limited clinical translation has been proposed to be due to limited tissue distribution and structural instability [ 310 , 311 ].…”

Section: Targeting Cd163 + Macrophagesmentioning

confidence: 99%

Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases

Skytthe

Graversen

Moestrup

2020

IJMS

140

View full text Add to dashboard Cite

The macrophage is a key cell in the pro- and anti-inflammatory response including that of the inflammatory microenvironment of malignant tumors. Much current drug development in chronic inflammatory diseases and cancer therefore focuses on the macrophage as a target for immunotherapy. However, this strategy is complicated by the pleiotropic phenotype of the macrophage that is highly responsive to its microenvironment. The plasticity leads to numerous types of macrophages with rather different and, to some extent, opposing functionalities, as evident by the existence of macrophages with either stimulating or down-regulating effect on inflammation and tumor growth. The phenotypes are characterized by different surface markers and the present review describes recent progress in drug-targeting of the surface marker CD163 expressed in a subpopulation of macrophages. CD163 is an abundant endocytic receptor for multiple ligands, quantitatively important being the haptoglobin-hemoglobin complex. The microenvironment of inflammation and tumorigenesis is particular rich in CD163+ macrophages. The use of antibodies for directing anti-inflammatory (e.g., glucocorticoids) or tumoricidal (e.g., doxorubicin) drugs to CD163+ macrophages in animal models of inflammation and cancer has demonstrated a high efficacy of the conjugate drugs. This macrophage-targeting approach has a low toxicity profile that may highly improve the therapeutic window of many current drugs and drug candidates.

show abstract

“…Since the discovery of Doxil TM [ 73 ], a liposomal-based nanocarrier for doxorubicin (DOX) currently used to treat metastatic breast cancer, liposomes have been the most clinically successful nanocarriers for the treatment of cancer [ 74 ]. Doxil TM , Myocet TM , and Lipusu TM are all liposomal formulations of different chemotherapies approved for breast cancer therapy.…”

Section: Acnps For Breast Cancer Therapymentioning

confidence: 99%

“…Other agents apart from DOX have also been included in ACNPs to treat breast cancer [ 73 , 74 , 75 , 76 , 77 , 78 ]. Similar to the use of DOX, taxanes have demonstrated significant toxicity in normal tissues for breast cancer therapy.…”

Section: Acnps For Breast Cancer Therapymentioning

confidence: 99%

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment

Juan

Cimas

Bravo³

et al. 2020

IJMS

View full text Add to dashboard Cite

Breast cancer is the most common invasive tumor in women and the second leading cause of cancer-related death. Nanomedicine raises high expectations for millions of patients as it can provide better, more efficient, and affordable healthcare, and it has the potential to develop novel therapeutics for the treatment of solid tumors. In this regard, targeted therapies can be encapsulated into nanocarriers, and these nanovehicles are guided to the tumors through conjugation with antibodies—the so-called antibody-conjugated nanoparticles (ACNPs). ACNPs can preserve the chemical structure of drugs, deliver them in a controlled manner, and reduce toxicity. As certain breast cancer subtypes and indications have limited therapeutic options, this field provides hope for the future treatment of patients with difficult to treat breast cancers. In this review, we discuss the application of ACNPs for the treatment of this disease. Given the fact that ACNPs have shown clinical activity in this clinical setting, special emphasis on the role of the nanovehicles and their translation to the clinic is placed on the revision.

show abstract

Clinical translation of immunoliposomes for cancer therapy: recent perspectives

Cited by 53 publications

References 80 publications

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications

Targeting of CD163+ Macrophages in Inflammatory and Malignant Diseases

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment

Contact Info

Product

Resources

About